Lactobacillus rhamnosus Benefits: Evidence-Based Guide to Anxiety, Weight Loss & Women's Health
What clinical research reveals about one of the most studied probiotic strains—and how it supports the gut-brain axis, metabolic health, and vaginal flora
Among the hundreds of probiotic strains available today, Lactobacillus rhamnosus stands out as one of the most extensively researched. First isolated in 1983, this versatile bacterium has accumulated an impressive body of clinical evidence spanning digestive health, mental wellbeing, weight management, and women's urogenital health.
What makes L. rhamnosus particularly interesting is its unique ability to survive the harsh conditions of the gastrointestinal tract. Unlike many probiotic strains that perish in stomach acid, L. rhamnosus possesses specialized surface proteins called pili that allow it to adhere to intestinal cells and persist in the gut—giving it time to exert meaningful effects on the gut microbiota and beyond.[1]
This guide examines what peer-reviewed research actually shows about L. rhamnosus benefits, which specific strains demonstrate clinical efficacy, and how this probiotic fits into a comprehensive approach to gut health optimization.
Key Takeaways
- L. rhamnosus modulates GABA receptors in the brain via the vagus nerve, reducing stress-induced corticosterone and anxiety-related behavior in preclinical studies—effects that were eliminated when the vagus nerve was severed.[2]
- Clinical trials show significant weight loss in women supplementing with L. rhamnosus CGMCC1.3724—losing an average of 4.4 kg versus 2.6 kg on placebo over 12 weeks, with continued loss during maintenance.[3]
- Oral L. rhamnosus GR-1 restores vaginal flora in 37% of women with asymptomatic bacterial vaginosis within 60 days, compared to just 13% on placebo—demonstrating the gut-vaginal connection.[4]
- Meta-analysis confirms L. rhamnosus GG reduces antibiotic-associated diarrhea from 22.4% to 12.3% across 12 randomized controlled trials involving nearly 1,500 participants.[5]
- Strain-specific effects are critical—not all L. rhamnosus strains produce the same benefits. GG excels for digestive health, GR-1 for vaginal health, and JB-1 for anxiety-related outcomes.
- Multi-strain formulations combining L. rhamnosus with complementary species like Bifidobacterium and L. reuteri may offer synergistic benefits across multiple health domains.[6]
What Is Lactobacillus rhamnosus?
Lactobacillus rhamnosus is a gram-positive, facultatively anaerobic bacterium belonging to the Lactobacillus genus. Originally classified as a subspecies of L. casei, it was reclassified as a distinct species in 1989 based on DNA hybridization studies. The species name "rhamnosus" refers to its ability to ferment rhamnose, a sugar that distinguishes it from closely related species.
What sets L. rhamnosus apart from many other lactobacilli is its exceptional acid and bile tolerance. While the stomach's pH can drop below 2—conditions lethal to most bacteria—L. rhamnosus strains have evolved mechanisms to survive this hostile environment and reach the intestines in viable numbers.[1]
Key Structural Features
The L. rhamnosus GG strain possesses unique SpaCBA pili—hair-like protein structures on its surface. These pili bind to mucus and intestinal cells, allowing the bacterium to persist in the gut longer than non-piliated strains. This extended residence time may explain why L. rhamnosus GG produces more consistent clinical effects than some competitors.[1]
How L. rhamnosus Differs from Other Lactobacillus Species
While all Lactobacillus species produce lactic acid through carbohydrate fermentation, L. rhamnosus has several distinguishing characteristics: superior acid and bile resistance enabling gut survival, unique adhesion proteins (pili) for intestinal colonization, production of specific bioactive compounds that modulate immune function, and the ability to colonize both the gut and vaginal microbiome when taken orally.
For those experiencing digestive symptoms, our guide on signs of Lactobacillus deficiency explores how to recognize when your microbiome may need support.
Anxiety & Mental Health: The Gut-Brain Connection
Perhaps no probiotic research has generated more excitement than the landmark 2011 study from Bravo and colleagues published in the Proceedings of the National Academy of Sciences. This groundbreaking work demonstrated that oral administration of L. rhamnosus JB-1 could alter brain chemistry and reduce anxiety-related behavior in mice—and that these effects were entirely dependent on an intact vagus nerve.[2]
Landmark Study: GABA Receptor Modulation via the Vagus Nerve
Mice receiving L. rhamnosus JB-1 for 28 days showed region-dependent alterations in GABAB1b mRNA expression—increases in the prefrontal cortex (associated with executive function) and decreases in the hippocampus and amygdala (regions involved in fear and emotional processing). These neurochemical changes were accompanied by reduced stress-induced corticosterone (the mouse equivalent of cortisol) and decreased anxiety- and depression-related behaviors.
Critically, when researchers severed the vagus nerve before treatment, L. rhamnosus no longer produced any neurochemical or behavioral effects—establishing the vagus as the primary communication pathway between gut bacteria and the brain.[2]
How L. rhamnosus Affects GABA Signaling
GABA (gamma-aminobutyric acid) is the brain's primary inhibitory neurotransmitter, playing crucial roles in reducing neuronal excitability and regulating anxiety. Alterations in GABA receptor expression have been implicated in the pathogenesis of both anxiety disorders and depression.
The Bravo study found that L. rhamnosus JB-1 produced the following specific changes in GABA receptor mRNA:
- GABAAα2 receptors: Reduced expression in the prefrontal cortex and amygdala, but increased in the hippocampus
- GABAB1b receptors: Increased expression in cingulate and prelimbic cortical regions, reduced in the hippocampus, amygdala, and locus coeruleus
These region-specific changes align with reduced anxiety and improved stress resilience—suggesting that L. rhamnosus doesn't simply increase or decrease GABA signaling globally, but rather rebalances it across brain regions in a potentially therapeutic pattern.
Human Clinical Evidence: More Complex
While the preclinical data is compelling, human trials have produced mixed results. A 2017 randomized controlled trial in healthy young men found that 4 weeks of L. rhamnosus JB-1 supplementation did not significantly alter stress responses, anxiety, or cognitive performance.[7]
Why Human Results May Differ
Several factors may explain the discrepancy between animal and human findings: healthy subjects may lack the baseline dysfunction needed to show improvement, stress paradigms in human trials are less severe than animal models, the dose used (1 × 109 CFU) may have been insufficient for humans, and individual microbiome composition may influence response. Ongoing research is examining whether L. rhamnosus benefits may be more pronounced in clinical populations with anxiety or mood disorders.
More recent research using L. rhamnosus GG has shown promising results. A 2025 study in rats demonstrated that LGG had antidepressant properties comparable to—and in some measures exceeding—the pharmaceutical antidepressants bupropion and venlafaxine, with improvements in BDNF levels, receptor expression, and reduced neuroinflammation.[8]
Multi-Strain Probiotic Support for Gut-Brain Health
MicroBiome Restore includes L. rhamnosus alongside 25 other clinically relevant strains—including L. plantarum and multiple Bifidobacterium species also studied for cognitive benefits. Our filler-free formula delivers 15 billion CFU per serving.
Weight Loss & Metabolic Health
The relationship between gut bacteria and body weight has become one of the most active areas of microbiome research. L. rhamnosus has emerged as one of the few probiotic strains with clinical evidence supporting weight loss benefits—though the effects appear to be notably sex-specific.
Landmark Study: Weight Loss in Women
A 24-week double-blind, placebo-controlled trial published in the British Journal of Nutrition examined 125 obese men and women. Those receiving L. rhamnosus CGMCC1.3724 (with oligofructose and inulin) underwent 12 weeks of caloric restriction followed by 12 weeks of weight maintenance.
Key findings for women:
- Average weight loss of 4.4 kg vs. 2.6 kg on placebo during the diet phase (P = 0.02)
- Continued weight loss during maintenance, while placebo group regained weight
- Significant reductions in fat mass and circulating leptin concentrations
- Changes in Lachnospiraceae family bacteria in fecal samples
For men: No significant differences between probiotic and placebo groups were observed at any time point.[3]
Notably, a 2023 study in mSystems found that L. rhamnosus M9 reduced diastolic blood pressure by over 20% in hypertensive models — learn more in our deep dive on probiotics and blood pressure.
Why Gender Differences?
The sex-specific effects of L. rhamnosus on weight loss remain incompletely understood. Researchers have proposed several hypotheses: women and men have different baseline gut microbiota compositions, hormonal differences may influence probiotic metabolism, the dose may have been insufficient for male body mass, and estrogen's effects on gut permeability may enhance probiotic efficacy in women.
L. rhamnosus also features prominently in PCOS research, where it was included in a landmark 6-month trial that significantly restored menstrual regularity, reduced testosterone, and improved quality of life in women with polycystic ovary syndrome. For the full clinical picture, see our guide to probiotics for PCOS.
Metabolic Mechanisms
Beyond direct weight loss, L. rhamnosus appears to improve several metabolic parameters:
- Leptin regulation: Studies show L. rhamnosus GG can improve leptin responsiveness in diet-induced obesity, potentially addressing the leptin resistance that makes sustained weight loss so difficult[9]
- Insulin sensitivity: Multiple studies demonstrate improved glucose tolerance and insulin sensitivity with L. rhamnosus supplementation
- Hepatic fat accumulation: L. rhamnosus GG has been shown to reduce liver fat through AMPK phosphorylation
- Appetite regulation: Follow-up research showed L. rhamnosus supplementation improved satiety efficiency and reduced disinhibited eating behaviors[10]
Strain Spotlight: L. rhamnosus GG for Metabolic Health
L. rhamnosus GG (LGG) is one of the most studied probiotic strains for metabolic applications. Research in mice fed high-fat diets shows that LGG supplementation significantly reduces body weight gain, epididymal fat weight, and hepatic lipid accumulation compared to high-fat diet controls. These effects appear to be mediated through modulation of gut microbiota composition and improved leptin signaling.[9]
For those also struggling with digestive discomfort, weight management challenges often coincide with gut issues—our guide on probiotics for bloating relief addresses both concerns.
Women's Health & Vaginal Flora Support
The vaginal microbiome plays a critical role in women's urogenital health. A healthy vaginal ecosystem is dominated by Lactobacillus species that produce lactic acid and hydrogen peroxide, maintaining an acidic environment (pH 3.8-4.5) that inhibits pathogenic bacteria and yeast. When this balance is disrupted—as in bacterial vaginosis—the risk of urinary tract infections, sexually transmitted infections, and pregnancy complications increases significantly.
One of the most compelling applications of L. rhamnosus is in maternal-infant health—the ProPACT trial found that supplementation during pregnancy and breastfeeding reduced infant eczema risk by 40%. See our full guide to probiotics for eczema for more comprehensive insights.
On a side note, L. rhamnosus GG demonstrates strong evidence for preventing antibiotic-associated diarrhea in children and has also shown emerging efficacy for treating infantile colic.
Remarkably, oral probiotic supplementation can influence vaginal microbiota. Lactobacillus species taken by mouth can travel through the digestive tract, survive passage through the anus, cross the perineum, and colonize the vaginal tract—a journey of approximately 7 days.[11]
Clinical Evidence: Oral Probiotics Restore Vaginal Flora
A randomized, placebo-controlled trial in 64 healthy women demonstrated that daily oral supplementation with L. rhamnosus GR-1 and L. fermentum RC-14 for 60 days significantly altered vaginal microbiota. Among women with asymptomatic bacterial vaginosis at baseline, 37% showed restoration to normal lactobacilli-dominated flora with probiotic treatment, compared to just 13% on placebo (P = 0.02).[4]
Additional findings included significant increases in vaginal lactobacilli at days 28 and 60, significant reduction in yeast at day 28, and significant reduction in coliforms at days 28, 60, and 90.
Bacterial Vaginosis Treatment
Bacterial vaginosis (BV) affects an estimated 30% of women at some point and is characterized by a shift from Lactobacillus-dominant flora to a polymicrobial environment with increased Gardnerella vaginalis and other anaerobes. Standard antibiotic treatment has high recurrence rates, making adjunctive probiotic therapy an attractive option.
Multiple clinical trials have examined L. rhamnosus strains for BV treatment:
- L. rhamnosus GR-1 + L. reuteri RC-14 with metronidazole: A study of 125 women with BV found that adding oral probiotics to standard antibiotic therapy improved cure rates compared to antibiotics alone[12]
- L. rhamnosus TOM 22.8: A recent systematic review identified this strain at 10 × 109 CFU/day for 10 days as highly effective, with 96.7% of patients showing improved Nugent scores[13]
- L. rhamnosus BMX 54: Used as adjuvant treatment, this strain significantly improved BV cure rates and reduced recurrence[14]
Strain Specificity Matters for Vaginal Health
Not all L. rhamnosus strains are effective for urogenital applications. L. rhamnosus GG, while excellent for digestive health, is not suited for vaginal colonization. The GR-1 strain was specifically isolated from the female urogenital tract and possesses surface characteristics that enable vaginal adhesion. When selecting a probiotic for women's health, strain designation is critical.
UTI Prevention
Urinary tract infections affect approximately 50% of women at some point in their lives, with high recurrence rates. Research suggests that L. rhamnosus GR-1 (typically combined with L. reuteri RC-14) can reduce UTI recurrence through competitive exclusion of uropathogens and enhancement of local immune defenses.
Early studies by Reid and colleagues showed that oral lactobacilli supplementation reduced colonization of the vagina by potential uropathogens including E. coli, Enterococcus, and Candida species—the organisms most commonly responsible for UTIs.[15]
Women experiencing recurrent infections may also benefit from understanding the role of Bifidobacterium in overall immune function.
L. rhamnosus demonstrates particular value for women during the menopausal transition, where research shows it supports both bone microarchitecture and vaginal flora restoration—two common concerns as estrogen levels decline.
Digestive Health & Diarrhea Prevention
The most robust clinical evidence for L. rhamnosus concerns its ability to prevent antibiotic-associated diarrhea (AAD)—a common and troublesome side effect affecting up to 30% of antibiotic courses. The L. rhamnosus GG strain has been particularly well-studied for this indication.
Meta-Analysis: Prevention of Antibiotic-Associated Diarrhea
A comprehensive 2015 meta-analysis by Szajewska and Kołodziej examined 12 randomized controlled trials encompassing 1,499 participants. Treatment with L. rhamnosus GG compared to placebo or no additional treatment reduced the risk of antibiotic-associated diarrhea from 22.4% to 12.3%—a relative risk reduction of 51% (RR: 0.49, 95% CI: 0.29-0.83).[5]
The European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) now recommends high-dose LGG (≥5 billion CFU/day) for AAD prevention, started simultaneously with antibiotic treatment.[16]
Mechanisms of Gut Protection
L. rhamnosus GG protects the gut through multiple mechanisms:
- Epithelial barrier maintenance: LGG prevents disruption of tight junctions between intestinal cells, reducing "leaky gut"
- Competitive exclusion: By occupying adhesion sites on intestinal cells, LGG prevents pathogen attachment
- Antimicrobial production: LGG produces bacteriocins and other compounds active against enteropathogens
- Immune modulation: LGG enhances secretory IgA production and regulates inflammatory cytokines
- Short-Chain Fatty Acid (SCFA) & Butyrate Production: L. rhamnosus participates in lactate-based cross-feeding that ultimately supports butyrate production—our SCFA and butyrate guide details how this bacterial teamwork functions.
Beyond its well-known immune and digestive benefits, L. rhamnosus CGMCC1.3724 showed significant weight loss results in women across a 24-week clinical trial — see how it compares to other strains in our probiotics for belly fat evidence review.
Acute Gastroenteritis in Children
Multiple meta-analyses have examined LGG for treating acute diarrhea in children. While earlier analyses showed benefit, a large 2018 trial published in the New England Journal of Medicine found no significant difference between LGG and placebo for acute gastroenteritis in children presenting to North American emergency departments.[17]
Interestingly, European studies have generally shown more positive results—leading some researchers to hypothesize that baseline microbiome differences between populations may influence probiotic efficacy. Updated meta-analyses suggest LGG may still be beneficial, particularly in European populations and for longer diarrhea episodes.[18]
L. rhamnosus GG is ranked as the single most effective strain for preventing antibiotic-associated diarrhea, reducing AAD risk by over 50% in clinical trials.
Irritable Bowel Syndrome (IBS)
Evidence for L. rhamnosus in IBS is less robust than for diarrhea prevention, but some studies suggest benefit—particularly for IBS-D (diarrhea-predominant) and IBS-A (alternating) subtypes. The effects may be mediated through the gut-brain axis and modulation of visceral hypersensitivity.
For comprehensive IBS support, multi-strain probiotics combining L. rhamnosus with other species may offer broader benefits than single-strain supplements.
Complete Probiotic Support with L. rhamnosus and 25 Additional Strains
MicroBiome Restore delivers L. rhamnosus as part of a comprehensive 26-strain formula including L. plantarum, L. reuteri, L. acidophilus, and five Bifidobacterium species—all in a filler-free prebiotic pullulan capsule.
Dosage Guidelines
Probiotic dosing remains challenging because effects are strain-specific and individual responses vary based on baseline microbiome composition. However, clinical trials provide guidance for L. rhamnosus applications:
Evidence-Based Dosing by Indication
| Indication | Strain | Dosage (CFU/day) | Duration |
|---|---|---|---|
| Antibiotic-associated diarrhea prevention | L. rhamnosus GG | ≥5 × 109 (5 billion) | Duration of antibiotic course + 1-2 weeks |
| Weight management (women) | L. rhamnosus CGMCC1.3724 | 3.2 × 108 with prebiotics | 12-24 weeks |
| Vaginal flora support | L. rhamnosus GR-1 (+ L. reuteri RC-14) | 1-2 × 109 of each strain | 30-60 days |
| Bacterial vaginosis (adjunct) | L. rhamnosus TOM 22.8 | 10 × 109 (10 billion) | 10 days |
| General gut health maintenance | L. rhamnosus GG or multi-strain | 1-10 × 109 | Ongoing |
Timing Considerations
For optimal survival, take L. rhamnosus supplements with or shortly before a meal. The presence of food—particularly containing some fat—buffers stomach acid and improves probiotic transit to the intestines.
When taking antibiotics, administer probiotics at least 2-3 hours apart from antibiotic doses to minimize direct contact. For comprehensive timing guidance, see our article on the best time to take probiotics.
Strain Comparison: Not All L. rhamnosus Are Equal
One of the most important concepts in probiotic science is strain specificity. Two strains of the same species can have dramatically different effects. This is well-illustrated within L. rhamnosus:
Major L. rhamnosus Strains and Their Applications
| Strain | Primary Applications | Key Evidence |
|---|---|---|
| L. rhamnosus GG (ATCC 53103) | Digestive health, diarrhea prevention, immune support | Most studied probiotic strain globally; ESPGHAN recommended for AAD |
| L. rhamnosus GR-1 | Vaginal health, UTI prevention, bacterial vaginosis | Isolated from female urogenital tract; travels from gut to vagina |
| L. rhamnosus JB-1 | Anxiety, stress response, gut-brain axis | Landmark PNAS study showing GABA modulation via vagus nerve |
| L. rhamnosus CGMCC1.3724 | Weight management (especially in women) | RCT showing sustained weight loss in women over 24 weeks |
| L. rhamnosus TOM 22.8 | Bacterial vaginosis treatment | Systematic review identified as most effective for BV |
| L. rhamnosus HN001 | Immune function, pregnancy support | Studies in pregnancy show reduced postnatal depression risk |
Why Multi-Strain Formulations May Be Advantageous
Given that different L. rhamnosus strains excel at different applications—and that gut health involves multiple interconnected systems—formulations combining L. rhamnosus with complementary species may provide broader coverage. For example, combining L. rhamnosus with L. plantarum (strong anti-inflammatory properties) and Bifidobacterium longum (excellent for stress resilience) creates a more comprehensive approach to gut-brain health.
L. rhamnosus also shows promise for prostate health—studies demonstrate it effectively inhibits E. coli and other pathogens responsible for bacterial prostatitis while attenuating inflammation in prostatic tissue, as explored in our comprehensive probiotics for prostate health guide.
Safety & Side Effects
L. rhamnosus has an excellent safety profile supported by decades of use and hundreds of clinical trials. The U.S. FDA has granted GRAS (Generally Recognized as Safe) status to multiple strains, and the European Food Safety Authority (EFSA) has included L. rhamnosus on its QPS (Qualified Presumption of Safety) list.
Common Side Effects
Most side effects are mild and transient, typically occurring as the gut microbiome adjusts to the new bacteria:
- Mild bloating or gas: Usually resolves within 1-2 weeks
- Temporary increase in bowel movements: Generally normalizes with continued use
- Mild abdominal discomfort: More common at higher doses or with rapid initiation
Populations Requiring Caution
While L. rhamnosus is safe for most people, certain populations should consult healthcare providers before supplementing:
- Immunocompromised individuals: Rare cases of bacteremia have been reported
- Patients with central venous catheters: Theoretical risk of contamination
- Those with severe acute pancreatitis: One study showed increased mortality with probiotic use
- Premature infants: Should only receive probiotics under medical supervision
For the vast majority of healthy individuals, L. rhamnosus supplementation is safe and well-tolerated. Starting with a lower dose and gradually increasing can minimize initial adjustment symptoms.
Frequently Asked Questions
Is Lactobacillus rhamnosus good for anxiety?
Preclinical research strongly suggests L. rhamnosus JB-1 can reduce anxiety through GABA receptor modulation and vagus nerve signaling. However, human trials have shown mixed results—healthy adults may not experience significant changes, while those with existing anxiety may benefit more. The gut-brain axis research is promising but still evolving.
How much L. rhamnosus should I take daily?
Dosing depends on your goal. For antibiotic-associated diarrhea prevention, clinical guidelines recommend at least 5 billion CFU of L. rhamnosus GG daily. For general gut health maintenance, 1-10 billion CFU is typical. For vaginal health applications, 1-2 billion CFU of the GR-1 strain (usually combined with L. reuteri RC-14) has shown benefit in studies.
Can L. rhamnosus help with weight loss?
Clinical trial evidence suggests L. rhamnosus CGMCC1.3724 can enhance weight loss in women when combined with caloric restriction and prebiotic fiber. Women in the probiotic group lost significantly more weight and continued losing during maintenance, while the placebo group regained weight. Interestingly, no effect was seen in men in the same study.
What's the difference between L. rhamnosus GG and L. rhamnosus GR-1?
These are different strains with different applications. GG (Gorbach-Goldin) was isolated from a healthy human intestine and excels at digestive health and immune support. GR-1 was isolated from the female urogenital tract and is specifically suited for vaginal health applications—it can travel from the gut to colonize the vaginal microbiome. For vaginal health, GR-1 is the evidence-based choice.
How long does it take for L. rhamnosus to work?
Timeline varies by application. For antibiotic-associated diarrhea prevention, benefits occur during the antibiotic course. For vaginal flora changes, studies show measurable differences at 28-60 days. For metabolic effects like weight loss, 12-24 weeks of consistent use is typically needed. Initial gut adjustment symptoms usually resolve within 1-2 weeks.
Can I take L. rhamnosus during pregnancy?
Most L. rhamnosus strains are considered safe during pregnancy, and some studies specifically examine pregnancy applications. L. rhamnosus HN001 has been studied for reducing postnatal depression symptoms. L. rhamnosus GR-1 has been evaluated for preventing bacterial vaginosis during pregnancy. However, always consult your healthcare provider before starting any supplement during pregnancy.
This vaginal colonization pathway is one reason L. rhamnosus is increasingly studied as part of probiotic strategies for fertility and conception, where restoring Lactobacillus dominance in the reproductive tract is a core goal.
Does L. rhamnosus need to be refrigerated?
L. rhamnosus stability varies by formulation. Many modern formulations use stabilization technology that allows shelf-stable storage. Freeze-dried products are generally stable at room temperature. However, refrigeration typically extends viability for all probiotics. Check your specific product's storage recommendations—quality formulations will maintain their stated CFU through the expiration date when stored as directed.
Conclusion: A Versatile Strain with Evidence-Based Applications
Lactobacillus rhamnosus represents one of the most well-researched probiotic species available, with clinical evidence spanning digestive health, mental wellbeing, metabolic function, and women's urogenital health. Its unique structural features—particularly the SpaCBA pili enabling intestinal adhesion—may explain why it consistently outperforms many other probiotic strains in clinical trials.
The key to benefiting from L. rhamnosus lies in understanding strain specificity. GG for digestive health and immune support. GR-1 for vaginal flora and UTI prevention. JB-1 for potential gut-brain applications. And CGMCC1.3724 for metabolic support in women. Different strains, different benefits.
For those seeking comprehensive probiotic support, formulations that combine L. rhamnosus with complementary strains—including other Lactobacillus species and Bifidobacterium—may offer the broadest range of benefits. The emerging science of synbiotics, combining such probiotics with prebiotic fibers that fuel their growth, represents the next frontier in evidence-based gut health optimization.
For more information on building a comprehensive gut health strategy, explore our guide to the top 10 probiotic strains for gut health.
Experience Science-Backed Probiotic Support
MicroBiome Restore combines L. rhamnosus with 25 additional probiotic strains and 9 organic prebiotics in a filler-free, pullulan capsule formula. No magnesium stearate. No titanium dioxide. No cellulose. Just 15 billion CFU of clinically relevant bacteria designed for optimal gut health.
References
- Segers, M. E., & Lebeer, S. (2014). Towards a better understanding of Lactobacillus rhamnosus GG-host interactions. Microbial Cell Factories, 13(Suppl 1), S7. https://doi.org/10.1186/1475-2859-13-S1-S7
- Bravo, J. A., Forsythe, P., Chew, M. V., Escaravage, E., Savignac, H. M., Dinan, T. G., Bienenstock, J., & Cryan, J. F. (2011). Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. Proceedings of the National Academy of Sciences, 108(38), 16050-16055. https://doi.org/10.1073/pnas.1102999108
- Sanchez, M., Darimont, C., Drapeau, V., Emady-Azar, S., Lepage, M., Rezzonico, E., Ngom-Bru, C., Berger, B., Philippe, L., Ammon-Zuffrey, C., Leone, P., Chevrier, G., St-Amand, E., Marette, A., Doré, J., & Tremblay, A. (2014). Effect of Lactobacillus rhamnosus CGMCC1.3724 supplementation on weight loss and maintenance in obese men and women. British Journal of Nutrition, 111(8), 1507-1519. https://doi.org/10.1017/S0007114513003875
- Reid, G., Charbonneau, D., Erb, J., Kochanowski, B., Beuerman, D., Poehner, R., & Bruce, A. W. (2003). Oral use of Lactobacillus rhamnosus GR-1 and L. fermentum RC-14 significantly alters vaginal flora: randomized, placebo-controlled trial in 64 healthy women. FEMS Immunology & Medical Microbiology, 35(2), 131-134. https://doi.org/10.1016/S0928-8244(02)00465-0
- Szajewska, H., & Kołodziej, M. (2015). Systematic review with meta-analysis: Lactobacillus rhamnosus GG in the prevention of antibiotic-associated diarrhoea in children and adults. Alimentary Pharmacology & Therapeutics, 42(10), 1149-1157. https://doi.org/10.1111/apt.13404
- Merenstein, D., Pot, B., Leyer, G., Ouwehand, A. C., Preidis, G. A., Elkins, C. A., Hill, C., Lewis, Z. T., Shane, A. L., Zmora, N., Petrova, M. I., Collado, M. C., Morelli, L., Montoya, G. A., Szajewska, H., Tancredi, D. J., & Sanders, M. E. (2023). Emerging issues in probiotic safety: 2023 perspectives. Gut Microbes, 15(1), 2185034. https://doi.org/10.1080/19490976.2023.2185034
- Kelly, J. R., Allen, A. P., Temko, A., Hutch, W., Kennedy, P. J., Faber, F., Murphy, E., Boylan, G., Bienenstock, J., Cryan, J. F., Clarke, G., & Dinan, T. G. (2017). Lost in translation? The potential psychobiotic Lactobacillus rhamnosus (JB-1) fails to modulate stress or cognitive performance in healthy male subjects. Brain, Behavior, and Immunity, 61, 50-59. https://doi.org/10.1016/j.bbi.2016.11.018
- Dursun, S., Coşkun, M., & Dursun, E. (2025). Promising Antidepressant Potential: The Role of Lactobacillus rhamnosus GG in Mental Health and Stress Response. Probiotics and Antimicrobial Proteins. https://doi.org/10.1007/s12602-025-10470-4
- Ji, Y., Park, S., Park, H., Hwang, E., Shin, H., Pot, B., & Holzapfel, W. H. (2019). Modulation of active gut microbiota by Lactobacillus rhamnosus GG in a diet-induced obesity murine model. Frontiers in Microbiology, 9, 710. https://doi.org/10.3389/fmicb.2018.00710
- Sanchez, M., Darimont, C., Panahi, S., Drapeau, V., Marette, A., Taylor, V. H., Doré, J., & Tremblay, A. (2017). Effects of a Diet-Based Weight-Reducing Program with Probiotic Supplementation on Satiety Efficiency, Eating Behaviour Traits, and Psychosocial Behaviours in Obese Individuals. Nutrients, 9(3), 284. https://doi.org/10.3390/nu9030284
- Yang, S., Reid, G., Challis, J. R. G., Gloor, G. B., Asztalos, E., Money, D., Seney, S., & Bhattacharjee, A. (2020). Effect of Oral Probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 on the Vaginal Microbiota, Cytokines and Chemokines in Pregnant Women. Nutrients, 12(2), 368. https://doi.org/10.3390/nu12020368
- Anukam, K., Osazuwa, E., Ahonkhai, I., Ngwu, M., Osemene, G., Bruce, A. W., & Reid, G. (2006). Augmentation of antimicrobial metronidazole therapy of bacterial vaginosis with oral probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14: randomized, double-blind, placebo controlled trial. Microbes and Infection, 8(6), 1450-1454. https://doi.org/10.1016/j.micinf.2006.01.003
- Phumkhamloet, S., Sirawattanapan, N., Wongkamhaeng, K., & Kanyong, P. (2025). Effective probiotic regimens for bacterial vaginosis treatment and recurrence prevention: A systematic review. Medicine, 104(1), e41213. https://doi.org/10.1097/MD.0000000000041213
- Recine, N., Palma, E., Domenici, L., Giorgini, M., Imperiale, L., Sassu, C., Municinò, M., & Benedetti Panici, P. (2016). Restoring vaginal microbiota: biological control of bacterial vaginosis. A prospective case-control study using Lactobacillus rhamnosus BMX 54 as adjuvant treatment against bacterial vaginosis. Archives of Gynecology and Obstetrics, 293, 101-107. https://doi.org/10.1007/s00404-015-3810-2
- Reid, G., Beuerman, D., Heinemann, C., & Bruce, A. W. (2001). Probiotic Lactobacillus dose required to restore and maintain a normal vaginal flora. FEMS Immunology & Medical Microbiology, 32(1), 37-41. https://doi.org/10.1111/j.1574-695X.2001.tb00531.x
- Szajewska, H., Canani, R. B., Guarino, A., Hojsak, I., Indrio, F., Kolacek, S., Orel, R., Shamir, R., Vandenplas, Y., van Goudoever, J. B., & Weizman, Z. (2023). Probiotics for the prevention of antibiotic-associated diarrhea in children. Journal of Pediatric Gastroenterology and Nutrition, 76(4), 523-531. https://doi.org/10.1097/MPG.0000000000003633
- Schnadower, D., Tarr, P. I., Casper, T. C., Gorelick, M. H., Dean, J. M., O'Connell, K. J., Mahajan, P., Levine, A. C., Bhatt, S. R., Roskind, C. G., Powell, E. C., Rogers, A. J., Vance, C., Sapien, R. E., Olsen, C. S., Metheney, M., Dickey, V. P., Hall-Moore, C., & Freedman, S. B. (2018). Lactobacillus rhamnosus GG versus Placebo for Acute Gastroenteritis in Children. New England Journal of Medicine, 379(21), 2002-2014. https://doi.org/10.1056/NEJMoa1802598
- Szajewska, H., Kołodziej, M., Gieruszczak-Białek, D., Skórka, A., Ruszczyński, M., & Shamir, R. (2019). Systematic review with meta-analysis: Lactobacillus rhamnosus GG for treating acute gastroenteritis in children—a 2019 update. Alimentary Pharmacology & Therapeutics, 49(11), 1376-1384. https://doi.org/10.1111/apt.15267
'%3e%3cg%20id='Final-Copy-2_2_'%20transform='translate(1275.000000,%20200.000000)'%3e%3cpath%20class='st0'%20d='M7.4,12.8h6.8l3.1-11.6H7.4C4.2,1.2,1.6,3.8,1.6,7S4.2,12.8,7.4,12.8z'/%3e%3c/g%3e%3c/g%3e%3c/g%3e%3cg%20id='final---dec.11-2020'%3e%3cg%20id='_x30_208-our-toggle'%20transform='translate(-1275.000000,%20-200.000000)'%3e%3cg%20id='Final-Copy-2'%20transform='translate(1275.000000,%20200.000000)'%3e%3cpath%20class='st1'%20d='M22.6,0H7.4c-3.9,0-7,3.1-7,7s3.1,7,7,7h15.2c3.9,0,7-3.1,7-7S26.4,0,22.6,0z%20M1.6,7c0-3.2,2.6-5.8,5.8-5.8%20h9.9l-3.1,11.6H7.4C4.2,12.8,1.6,10.2,1.6,7z'/%3e%3cpath%20id='x'%20class='st2'%20d='M24.6,4c0.2,0.2,0.2,0.6,0,0.8l0,0L22.5,7l2.2,2.2c0.2,0.2,0.2,0.6,0,0.8c-0.2,0.2-0.6,0.2-0.8,0%20l0,0l-2.2-2.2L19.5,10c-0.2,0.2-0.6,0.2-0.8,0c-0.2-0.2-0.2-0.6,0-0.8l0,0L20.8,7l-2.2-2.2c-0.2-0.2-0.2-0.6,0-0.8%20c0.2-0.2,0.6-0.2,0.8,0l0,0l2.2,2.2L23.8,4C24,3.8,24.4,3.8,24.6,4z'/%3e%3cpath%20id='y'%20class='st3'%20d='M12.7,4.1c0.2,0.2,0.3,0.6,0.1,0.8l0,0L8.6,9.8C8.5,9.9,8.4,10,8.3,10c-0.2,0.1-0.5,0.1-0.7-0.1l0,0%20L5.4,7.7c-0.2-0.2-0.2-0.6,0-0.8c0.2-0.2,0.6-0.2,0.8,0l0,0L8,8.6l3.8-4.5C12,3.9,12.4,3.9,12.7,4.1z'/%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
Your Privacy Choices
Share and get 15% off!
Simply share this product on one of the following social networks and you will unlock 15% off!